

# NEUROMICS



## Delta Opioid Receptor<sup>3-17</sup>

## Data Sheet

<b>Catalog Number:</b>	RA19072	<b>Host:</b>	Rabbit
<b>Product Type:</b>	Affinity Purified Antibody	<b>Species Reactivity:</b>	Rat; Human; Mouse
<b>Immunogen Sequence:</b>	Synthetic peptide comprising residues 3-17 LVPSARAEIQSSPLV of the mouse and rat DOR-1 protein. Reacts with human DOR-1 as well.	<b>Format:</b>	Liquid. 100 ug in 100 ul (1 mg/ml) in PBS containing 0.02% sodium azide
<b>Applications:</b>	Western blot: 1:500-1,000 dilution Immunohistochemistry: 1:500-1:15,000 Immunofluorescence: 1:4,000-1:60,000 (See PNAS July 20, 2010 vol. 107 no. 29 13117-13122.)		
	*Dilutions listed as a recommendation. Optimal dilution should be determined by investigator.		
<b>Storage:</b>	Maintain at +2-8°C for 3 months or at -20°C for longer periods. Stable for 1 year. Avoid repeated freeze-thaw cycles.		
<b>References:</b>	<a href="#">Hai-Bo Wanga, Bo Zhaoa, Yan-Qing Zhonga, Kai-Cheng Li, Zi-Yan Li, Qiong Wang, Yin-Jing Lua, Zhen-Ning Zhang, Shao-Qiu He, Han-Cheng Zheng, Sheng-Xi Wu, Tomas G. M. Hökfelt, Lan Baob, and Xu Zhanga. Coexpression of δ- and μ-opioid receptors in nociceptive sensory neurons. PNAS July 20, 2010 vol. 107 no. 29 13117-13122.</a>		

### Application Notes


#### Western Blot:

The antibody may detect dimers or trimers on a Western blot as heterodimerization and homodimerization is common with the opioid receptors; however the monomer should be the dominant DOR-1 band at about 48 kDa

#### Immunostaining.

Adult rats, mice, and Oprd1 exon 1-deleted mice were fixed. Cryostat sections of L4 and L5 DRGs and spinal cord segments were processed for immunofluorescence staining (13) with Rb anti-DOR13-17 (1:2,000-1:60,000; DiaSorin and 1:4,000-1:60,000; Neuromics), Rb anti-DOR12-18 (1:30,000-1:120,000; Alomone), Rb anti-DOR1358-372 (1:1,000-1:2,000; Lifespan Biosciences), Rb anti-MOR (1:1,000; Neuromics); guinea pig anti-SP (1:500; Neuromics), and mouse anti-CGRP (1:1,000; Biogenesis) antibodies. IB4-labeling was carried out with fluorescein-labeled GSL I-IB4 (1:200). The Myc-DOR1-transfected HEK293 cells and neurons were fixed and processed with mouse anti-Myc antibodies (1:500; DSHB). Nuclear DAPI staining was used to indicate HEK293 cells in control experiments. See: *PNAS July 20, 2010 vol. 107 no. 29 13117-13122.*

*Image: Western blot analysis with DOR at a dilution of 1:500. Lane 1: 10 ug of human brain lysate and Lane 2: 10 ug rat brain lysate*




### FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. -v4-02/2012

[www.neuromics.com](http://www.neuromics.com)

Neuromics • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail [pshuster@neuromics.com](mailto:pshuster@neuromics.com)

Images: Distinct distribution patterns of DORs in subsets of DRG neurons of mice. Immunostaining with antibodies against DOR13–17 [A: 1:30,000, antibody 1 (ab #1); DiaSorin and C: antibody 2 (ab #2); Neuromics] shows DORs in small DRG neurons and afferent fibers in spinal laminae I–II. This immunostaining pattern is abolished by the antiserum preabsorption or the deletion of *Oprd1* exon 1. Reduction in immunostaining is quantitatively assayed by determining the percentage of positive DRG neurons (B;  $n = 6$ ) and fluorescence intensity (I<sub>flu.</sub>) in the laminae I–II (D;  $n = 5$ ). \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ . (Scale bars: A and C, 40  $\mu\text{m}$ ). DOR labeling (anti-DOR13–17, 1:30,000; DiaSorin) associated with vesicles in peptidergic small DRG neurons (E and F) is absent in *Oprd1* exon 1-deleted mice (G). Colocalization of DORs and neuropeptides is shown by correlated peaks of I<sub>flu.</sub> measured along lines. (Scale bar: 8  $\mu\text{m}$ ). (H) Immunostaining with antibodies against DOR12–18 (1:60,000; Alomone) shows the presence of DORs on the cell surface of large DRG neurons of mice. (Scale bar: 25  $\mu\text{m}$ ). This staining pattern is abolished by preabsorption and is absent in *Oprd1* exon 1-deleted mice. (Scale bar: 80  $\mu\text{m}$ ). (I) Triple-immunostaining shows that DOR+ large DRG neurons contain neither SP nor CGRP. (Scale bar: 80  $\mu\text{m}$ ). [www.pnas.org/cgi/doi/10.1073/pnas.1008382107](http://www.pnas.org/cgi/doi/10.1073/pnas.1008382107)



### Opioid Receptor Antibodies

Name	Catalog #	Type	Species	Applications	Size	Price
Delta Opioid Receptor 3-17	RA19072	Rabbit IgG	H; R	WB	100 ul	\$350
					100 ug Blocking Peptide	\$95
Delta Opioid Receptor 358-372	RA10101	Rabbit IgG	M; R	ICC	50 ul	\$145
					150 ul	\$348
					20 ug Blocking Peptide	\$95
Delta Opioid Receptor 361-372	RA19073	Rabbit IgG	H; M; R	IF; IHC; WB	100 ul	\$350
					100 ug Blocking Peptide	\$125
proDynorphin (guinea pig)	GP10109	Guinea Pig IgG	GP	IHC	50 ul	\$215
					150 ul	\$475
					20 ug Blocking Peptide	\$95
proDynorphin	GP10110	Guinea Pig IgG	M; R	IHC	50 ul	\$215
					150 ul	\$475
					20 ug Blocking Peptide	\$95
Endomorphin 1 and 2	RA21002	Rabbit IgG	H; M; Pr; R	IHC	50 ug	\$155
Endomorphin 2	RA10111	Rabbit IgG	Pr; R	IHC	100 ul	\$245
					100 ug Blocking Peptide	\$95

### FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. -v4-02/2012

[www.neuromics.com](http://www.neuromics.com)

Neuromics • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail [pshuster@neuromics.com](mailto:pshuster@neuromics.com)

Name	Catalog #	Type	Species	Applications	Size	Price
<b>beta-Endorphin</b>	RA21004	Rabbit IgG	R	IHC	50 ul	\$155
<b>Kappa Opioid Receptor</b>	RA10103	Rabbit IgG	H; M	ICC; IHC	50 ul. 150 ul. Blocking Peptide-20 ug.	\$145 \$348 \$95
<b>Kappa Opioid Receptor</b>	MO15098	Mouse IgG	H; M; R	IHC	100 ug	\$255
<b>Mu Opioid Receptor</b>	GP10106	Guinea Pig IgG	H; Pr; R	ICC; IHC	50 ul 100 ul 50 ul Blocking Peptide @ 2mgs/ml	\$225 \$375 \$95
<b>Mu Opioid Receptor</b>	RA10104	Rabbit IgG	H; M; Pr; R	ICC; IHC; WB	50 ul 150 ul 50 ul Blocking Peptide @ 2mgs/ml	\$155 \$360 \$95
<b>phospho-Mu Opioid Receptor (Ser375)</b>	RA18001	Rabbit IgG	H; M	ICC; WB; IP	100 ul	\$330
<b>MOR-1C</b>	RA20001	Rabbit IgG	M; R	IHC	50 ul 150 ul	\$155 \$368
<b>OPMC-L</b>	RA26002	Rabbit IgG	H; M; R; Rb	IHC; WB	100 ul	\$375
<b>ORL 1</b>	RA14140	Rabbit IgG	H; M; R	IF; IHC	100 ul 100 ul@1mg/ml Blocking Peptide	\$365 \$95
<b>ORL 1</b>	RA14133	Rabbit IgG	H; M; R	IF; IHC	100 ul 100 ul@1mg/ml Blocking Peptide	\$275 \$95
<b>Orphanin FQ/Nociceptin</b>	RA10106	Rabbit IgG	H; M; R	IHC	50 ul 150 ul 50 ul. @ 2 mg/ml. Blocking Peptide	\$145 \$348 \$95
<b>Orphanin FQ/Nociceptin</b>	GP10107	Guinea Pig IgG	H; M; R	IHC	50 ul 150 ul 50 ul. @2 mg/ml. Blocking Peptide	\$155 \$348 \$95

**FOR RESEARCH USE ONLY**

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-v4-02/2012

[www.neuromics.com](http://www.neuromics.com)

Neuromics • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail [pshuster@neuromics.com](mailto:pshuster@neuromics.com)